Product Code: RP-ID-10094781 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10094781
Market Overview:
Global Autoinjectors Market Segmentation by Type (Reusable, and Disposable); by End-User (Hospitals, Homecare, Retail Pharmacies, and Others); and by Purpose (Anaphylaxis, Multiple Sclerosis, Diabetes, Cardiovascular Diseases, Rheumatoid Arthritis, and Others)-Demand Analysis & Opportunity Outlook 2031
Global Autoinjectors Market Highlights Over 2022 - 2031
The global autoinjectors market is estimated to garner revenue by growing at a CAGR of ~18% over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of approximately USD 54.0 billion in the year 2021. The growth of the market can be attributed to the benefits provided by the autoinjectors in the form of reduced risk of needle stuck, decreasing phobia related to needles, proper dosage assurance, and others. As per the World Health Organization, approximately 262 million people were affected by asthma in 2019 and accounted for 461,000 deaths. Furthermore, autoinjectors are used to treat a wide range of chronic disease symptoms including asthma and can even be utilized by the patient in an emergency. Therefore, ease to use and other benefits are expected to drive the growth of the global autoinjectors market.
GET A SAMPLE COPY OF THIS REPORT
COVID-19 had a positive impact on the global autoinjectors market. The effect of COVID-19 was widespread and patients were asked to delay their non-essential treatments by the government restrictions. The healthcare infrastructure was not able to meet the demand of the patients owing to the large percentage of the population affected by the pandemic. Additionally, people become self-reliant for chronic diseases such as food allergies considering the deadly diseases present in hospitals and clinics. Therefore, the COVID-19 pandemic is anticipated to drive the growth of the global autoinjectors market.
The global autoinjectors market is segmented by end-user into hospitals, homecare, retail pharmacies, and others. Out of these, the homecare segment in the market is anticipated to have the largest growth over the forecast period. This can be attributed to the increase in cases of emergencies and is easy to use by patients and home takers. Moreover, there has been an increase in the number of diseases and allergies that require immediate medication, such as food allergies, asthma, and others. Additionally, rising awareness among the population for self-medication practices is anticipated to increase the growth of the homecare segment.
Global Autoinjectors Market Regional Synopsis
Regionally, the global autoinjectors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. On the strength of presence of advanced medical technological devices and developed healthcare infrastructure, the North America is expected to generate the largest revenue by the end of 2031. Moreover, the Asia Pacific region in the global autoinjectors market is estimated to witness noteworthy growth over the forecast period on the back of surge in healthcare expenditure and an increase in the population. China’s health expenditure is anticipated to rise to 9.1 % of GDP in 2035 from 5.6 % of GDP in 2015. A surge in healthcare expenditure is expected to easily move autoinjectors into the market. Hence, it is anticipated to drive the growth of the Asia Pacific region.
Market Segmentation
Our in-depth analysis of the global autoinjectors market includes the following segments:
By Type
-
Reusable
-
Disposable
By End-User
-
Hospitals
-
Homecare
-
Retail Pharmacies
-
Others
By Purpose
-
Anaphylaxis
-
Multiple Sclerosis
-
Diabetes
-
Cardiovascular Diseases
-
Rheumatoid Arthritis
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Autoinjectors Market
Growth Drivers
-
Requirement of medicine in case of emergency
-
Increase in the benefits of using autoinjectors, such as a lower risk of needle stucking.
-
Increasing prevalence of chronic diseases
Challenges
-
High cost of the autoinjectors
-
Lack of knowledge regarding autoinjectors
Key Companies Dominating the Global Autoinjectors Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global autoinjectors market that are included in our report are Johnson & Johnson Private Limited, Becton, Dickinson and Company, Amgen Inc., AbbVie Inc., Viatris Inc. (Mylan), Teva Pharmaceutical Industries Ltd., Pfizer Inc., BIOGEN INC., Antares Pharma, Inc., Bayer AG, and others.
Latest Developments in the Global Autoinjectors Market:
-
27 April 2020: Teva Pharmaceuticals USA, Inc., subsidiary of Teva Pharmaceutical Industries Ltd., announced the availability of the AJOVY treatment autoinjector device in the U.S. AJOVY is used as a treatment for people suffering from migraines.
-
11 June 2018: AbbVie GK subsidiary of AbbVie Inc., announced the launch of an autoinjector HUMIRA Pen for Monoclonal Antibody HUMIRA. The purpose behind the launch of HUMIRA Pen was to reduce the risk on patients while performing self-injection.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Johnson & Johnson Private Limited
- Becton Dickinson and Company
- Amgen Inc.
- AbbVie Inc.
- Viatris Inc. (Mylan)
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- BIOGEN INC.
- Antares PharmaInc.
- Bayer AG
Related Reports
Proof of Quality & Reliability
